Some studies have shown that rifaximin is effective in the management of Crohn's Disease. Meanwhile, its adverse effect is tolerable. But no study has been conducted to assess its effect on preventing postoperative recurrence. Thus, we conduct a randomised controlled study to assess the effect of rifaximin combined with thiopurine on preventing postoperative endoscopic recurrence in Crohn's disease, compared with thiopurine. The primary endpoint is the rate of endoscopic recurrence at 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
120
Antibiotics
immunomodulator
The Sixth Affiliated Hospital, Sun Yat-sen University
Guanzhou, Guangdong, China
RECRUITINGdifference of incidence of endoscopic recurrence
Endoscopic recurrence was defined by a score ≥i2 according to endoscopic recurrence score developed by Rutgeerts et al.
Time frame: 6 months after surgery
Adverse effect
Adverse effect of Rifaximin
Time frame: 6 months after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.